SAN DIEGO and VANCOUVER, British Columbia, Oct. 10, 2016 /PRNewswire/ -- Sophiris Bio Inc.
(NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical
company developing topsalysin (PRX302) for the treatment of
urological diseases, today announced that Randall E. Woods,
president and chief executive officer, will present a corporate
overview at the 2016 BIO Investor Forum. The presentation is
scheduled for Tuesday, October 18, 2016 at 10:30 a.m. PDT in San
Francisco.
The presentation will be webcast live and can be accessed
through the Investor Relations page at www.sophiris.com. A
replay of the presentation will be available on the Company's
website for 90 days.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing
topsalysin, a clinical-stage, targeted therapy for the treatment of
urological diseases. Topsalysin has successfully completed a Phase
3 clinical study for the treatment of the symptoms of benign
prostatic hyperplasia (BPH), and is designed to be as efficacious
as pharmaceuticals, less invasive than the surgical interventions,
and without the sexual side effects seen with existing treatments.
Topsalysin has also successfully completed a Phase 2a clinical
trial for the treatment of localized low to intermediate risk
prostate cancer. For more information, please visit
www.sophiris.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
Sophiris' current beliefs as well as assumptions made by and
information currently available to Sophiris and relate to, among
other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance
and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by Sophiris in its
public securities filings; actual events may differ materially from
current expectations. Sophiris disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company
Contact:
Peter
Slover
Chief Financial
Officer
(858)
777-1760
|
|
|
Corporate
Communications and Investor Relations:
|
Michael
Moore
NATIONAL
Equicom
Investor
Relations
(858)
886-7813
mmoore@national.ca
|
Jason
Spark
Canale
Communications
Corporate
Communications and IR
(619)
849-6005
jason@canalecomm.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-the-2016-bio-investor-forum-300341952.html
SOURCE Sophiris Bio Inc.